Clinical Trial Update: Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bendamustine (SDX-105) for safety and activity in patients with rituximab-refractory non-Hodgkin lymphoma; the study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Treanda (bendamustine) (bendamustine)

Snippet

Sponsor: Cephalon | Conditions: Non-Hodgkin's Lymphoma | Phase 2 | Status: COMPLETED